Intuitive Surgical vs Edwards Lifesciences
Side-by-side comparison of AI visibility scores, market position, and capabilities
Robotic surgery pioneer with 9,800+ da Vinci systems; da Vinci 5 adds haptic feedback; $8.35B FY2024 revenue; 57,000+ trained surgeons create switching costs; J&J and Medtronic competing.
About
Intuitive Surgical is the global pioneer and dominant leader in robotic-assisted minimally invasive surgery, founded in 1995 and headquartered in Sunnyvale, California. The company trades on Nasdaq (ISRG) and reported $8.35 billion in FY2024 revenue, representing approximately 17% year-over-year growth, with an installed base of nearly 9,800 da Vinci surgical systems deployed in hospitals across 70+ countries. The fourth-generation da Vinci 5 system—launched in 2024—introduced haptic force feedback for the first time, allowing surgeons to sense tissue resistance through robotic instruments, a breakthrough that strengthens Intuitive's technical moat and accelerates system upgrades among existing customers.
Irvine CA structural heart devices (NYSE: EW) at $5.44B 2024 revenue; 60% TAVR global share, EVOQUE tricuspid +88% in Q4, Critical Care sold to BD for $4.2B, JenaValve acquisition expanding to aortic regurgitation.
About
Edwards Lifesciences Corporation is an Irvine, California-based structural heart disease and hemodynamic monitoring technology company — publicly traded on the New York Stock Exchange (NYSE: EW) as an S&P 500 Healthcare component — designing, developing, and manufacturing devices for heart valve replacement, transcatheter heart valve therapy, and cardiac critical care through approximately 15,800 employees in 100+ countries. In fiscal year 2024, Edwards reported total revenue of $5.44 billion (+8.6% year-over-year), driven by its dominant Transcatheter Aortic Valve Replacement (TAVR) franchise commanding approximately 60% global market share and 70%+ US market share. The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment demonstrated exceptional growth, with Q4 TMTT revenue reaching $105 million (+88% year-over-year), as the EVOQUE tricuspid replacement system gained commercial momentum. In 2024, Edwards executed a major strategic transformation: divesting its Critical Care segment (hemodynamic monitoring) to Becton Dickinson for $4.2 billion — using the proceeds to fund two acquisitions: JenaValve Technology ($1.2B combined, expanding TAVR to high-risk patients with aortic regurgitation) and Endotronix. The company concentrates its entire focus on structural heart disease therapies.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.